Results for tag: "Kidney Transplant Rejection Drug"

The Kidney Transplant Rejection Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. These drugs are used to prevent or reduce the risk of organ rejection in patients who have undergone a kidney transplant. They are typically administered in combination with other immunosuppressant drugs, such as corticosteroids, to reduce the risk of organ rejection. Common side effects of these drugs include nausea, vomiting, diarrhea, and increased risk of infection. The Kidney Transplant Rejection Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Astellas Pharma, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. These companies are constantly developing new drugs and improving existing ones to meet the needs of patients. Show Less Read more